Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Division of Cancer Biology, Comparative Biomedicine Research Branch, Research Institute of National Cancer Center, Goyang, Korea.
J Clin Pathol. 2014 Jul;67(7):576-81. doi: 10.1136/jclinpath-2013-202163. Epub 2014 Apr 2.
Integrin αv subunits are involved in tumour angiogenesis and tumour progression in various types of cancers. Clinical trials evaluating agents targeting integrin αv are ongoing. Integrin αv expression has been reported in several cancers in association with tumour progression or poor survival. However, no study has addressed the prognostic influence of integrin αv expression on survival of patients with colorectal cancer (CRC).
Immunohistochemical staining of integrin αv was performed in 198 CRC samples to evaluate its prognostic significance.
High expression of integrin αv was observed in 58.1% (115/189) of colorectal adenocarcinoma samples, while only in 11.5% (3/26) of tubular adenoma samples and in none of normal mucosa or hyperplastic polyp samples. It was more frequently found in female patients and less frequently observed in well differentiated tumours. The proportion of cases with high expression of integrin αv showed an increasing trend with increased T stage (p=0.032), N stage (p=0.006) and TNM stage (p=0.001). Patients displaying exuberant expression of integrin αv showed shorter overall survival (p=0.001) and disease-free survival (p=0.004). Elevated integrin αv expression was an independent prognostic factor for overall survival (HR: 2.04, 95% CI 1.16 to 3.56; p=0.013) and disease-free survival (HR: 2.19, 95% CI 1.16 to 4.13; p=0.015).
Overexpression of integrin αv is associated with advanced T and N stage and as an independent prognostic factor in CRC.
整合素 αv 亚基参与多种类型癌症的肿瘤血管生成和肿瘤进展。正在进行评估靶向整合素 αv 的药物的临床试验。整合素 αv 的表达已在几种癌症中与肿瘤进展或不良预后相关报道。然而，尚无研究探讨整合素 αv 表达对结直肠癌（CRC）患者生存的预后影响。
对 198 例 CRC 样本进行整合素 αv 的免疫组织化学染色，以评估其预后意义。
189 例结直肠腺癌样本中，58.1%（115/189）观察到整合素 αv 高表达，而管状腺瘤样本中仅 11.5%（3/26），正常黏膜或增生性息肉样本中均未见。它在女性患者中更为常见，在分化良好的肿瘤中较少见。高表达整合素 αv 的病例比例随着 T 分期（p=0.032）、N 分期（p=0.006）和 TNM 分期（p=0.001）的增加而呈上升趋势。表现出整合素 αv 过度表达的患者总生存期（p=0.001）和无病生存期（p=0.004）更短。整合素 αv 表达升高是总生存期（HR：2.04，95%CI 1.16 至 3.56；p=0.013）和无病生存期（HR：2.19，95%CI 1.16 至 4.13；p=0.015）的独立预后因素。
整合素 αv 的过表达与 CRC 的 T 和 N 期进展有关，并且是独立的预后因素。
